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Abstract: Liraglutide is a glucagon-like peptide-1 analog with pharmacokinetic properties 
suitable for once-daily administration approved by the Food and Drug Administration for the 
treatment of patients with type 2 diabetes. Clinical trial data from large, controlled studies 
  demonstrate the safety and efficacy of liraglutide in terms of hemoglobin A1c (HbA1c) reduc-
tion, reductions in body weight, and the drug’s low risk for hypoglycemic events when used as 
monotherapy.   Liraglutide has been studied as monotherapy and in combination with metformin, 
glimepiride, and   rosiglitazone for the treatment of type 2 diabetes. Additionally, comparative 
data with insulin glargine and exenatide therapy are available from Phase III trials. Once-daily 
  administration may provide a therapeutic advantage for liraglutide over twice-daily exenatide, 
with similar improvements in HbA1c and body weight observed when liraglutide was compared 
with exenatide. The glucose-dependent mechanism of insulin release with incretin analog 
therapy holds potential clinical significance in the management of postprandial hyperglycemic 
excursions, with minimal risk of hypoglycemia when used with non-secretagogue medications. 
Data to date on patient-reported outcomes with liraglutide treatment are encouraging. The most 
common adverse events associated with liraglutide therapy are dose-dependent nausea, vomit-
ing, and diarrhea. Diligent postmarketing surveillance to elucidate the risk of pancreatitis and 
medullary thyroid carcinoma in a heterogeneous population are likely warranted.
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Introduction
The burden of diabetes continues to grow, both globally to more than 220 million people 
worldwide with diabetes1 and in the US, where more than 23.6 million people have 
the disease.2 Although numerous interventions and medications exist to treat diabetes, 
less than half of adults in the US with diabetes are able to reach the target glycosylated 
hemoglobin A1c (HbA1c) level, as set by the American Diabetes Association (ADA), of 
less than 7% for most patients.3,4 Attaining and maintaining glycemic control in type 2 
diabetes mellitus (T2DM) is complicated by disease progression and continued β-cell 
deterioration.5 Benefits of intensive glucose control include a reduction in microvascular 
complications, as well as the so-called “legacy effect”. This effect refers to the results 
of a 10-year follow-up study to the United Kingdom Prospective Diabetes Study, which 
found that intensive glucose control in newly diagnosed T2DM patients provided long-
term benefits on cardiovascular outcomes and mortality, even if intensive control was 
not sustained in the long term.6 Considering these findings, and that 18% of patients 
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Kingdom Prospective Diabetes Study,7 it is clear that glycemic 
control starting at the time of T2DM diagnosis is important.
While lifestyle modifications, including diet and exercise, 
were once the initial treatment for patients with T2DM, it is 
now recognized that these interventions are insufficient for 
most patients, and pharmacotherapy should not be delayed.8 
Thus, the initial management of a patient presenting with 
T2DM consists of both lifestyle modification and medica-
tion, most specifically metformin, as recommended by the 
ADA.9 While monotherapy may suffice in the short term, 
most patients will need polypharmacy to achieve and sustain 
glycemic control.5 The ADA recommends initial combination 
therapy in newly diagnosed patients with an HbA1c of .8.5%,9 
while a consensus panel for the American Association of 
Clinical Endocrinologists (AACE) and the American College 
of Endocrinology (ACE) is even more aggressive, recom-
mending dual therapy for patients with an HbA1c between 
7.6% and 9%, and triple therapy or insulin for those with an 
initial HbA1c of .9%.8
Because the choice of initial therapy and adjunctive 
therapy for intensification is increasingly individualized 
to the patient, agents that were once viewed solely as add-on 
therapy are now being considered much earlier in the course 
of treatment. Glucagon-like peptide-1 (GLP-1) agonists and 
dipeptidyl peptidase-4 (DPP-4) inhibitors are examples of 
such agents. The AACE/ACE diabetes algorithm recom-
mends monotherapy for patients with an initial HbA1c of 
6.5%–7.5%.8 While metformin is the preferred initial agent, 
GLP-1 receptor agonists, DPP-4 inhibitors, thiazolidin-
ediones, and alpha-glucosidase inhibitors are included as 
alternatives.8 For patients requiring dual or triple therapy, 
the AACE/ACE preferentially recommends the addition of 
a GLP-1 agonist or a DPP-4 inhibitor, citing their efficacy 
and safety profiles, over thiazolidinediones or sulfonylureas.8 
Following initial treatment with metformin, the ADA, in 
contrast, recommends intensification with either basal insulin 
or a sulfonylurea (both Tier 1, or well validated therapies), 
pioglitazone or a GLP-1 agonist (both Tier 2, or less well 
validated therapies).9 Not only have such treatment algo-
rithms changed in recent years to recommend GLP-1 agonists 
earlier, but package labeling is also changing to expand their 
use. Exenatide, the GLP-1 agonist approved by the Food and 
Drug Administration (FDA) in 2005 for combination therapy, 
received an indication for monotherapy in 2009.10
This relatively new class of GLP-1 agonists has gained 
increasing use for a variety of reasons. Agents which mimic 
the incretin system, such as GLP-1 agonists, have a low 
incidence of hypoglycemia, often cause weight loss, and may 
preserve β-cells or even stimulate their proliferation.11,12 In 
addition to the approval of exenatide, liraglutide was approved 
by the FDA in January 2010.13 This paper will provide an 
overview of liraglutide and attempt to compare this new 
incretin analog with exenatide in terms of efficacy, safety, 
and utility in the treatment of patients with T2DM.
Methods
A MEDLINE search (1966 – February 2010) was conducted 
with the key words “liraglutide” and “incretin therapies” 
for clinical trials and pertinent review articles published 
in English. References of identified articles were searched 
for additional relevant sources. Abstracts from the ADA 
and European Association for the Study of Diabetes annual 
meetings presented in 2006, 2007, 2008, and 2009 were 
also searched for relevant data. English language articles 
pertinent to the pharmacology, pharmacokinetics, efficacy, 
safety, and patient-related outcomes of liraglutide treatment 
were reviewed. Six Phase III clinical trials from the Lira-
glutide Effects and Action in Diabetes (LEAD) program 
have been published. Reports on patient-reported outcomes 
and quality of life measures have also been published and 
are discussed herein.
Pharmacology
A role for an intestinal mediator of insulin secretion was 
initially conceived by the observation that the oral intake 
of glucose resulted in a greater insulin response when 
compared with intravenous glucose administration.14,15 This 
“incretin effect” is now known to be due to the stimulation 
of insulin release by the oral intake of nutrients which results 
in insulin secretion above and beyond the insulin release 
induced by increased blood glucose concentrations alone. 
The incretin effect is now recognized as being responsible 
for approximately 60% of the insulin response to a given 
meal.16 Of clinical significance, the incretin effect has been 
shown to be greatly impaired in patients with T2DM.17 The 
incretin effect is primarily attributed to 2 insulinotropic gut 
hormones, ie, GLP-1 and glucose-dependent insulinotropic 
polypeptide (GIP). GLP-1 is a 30-amino acid peptide released 
from L-cells of the intestine in response to a meal,18 and GIP 
is released by duodenal cells of the proximal small bowel.19 
GLP-1 secretion is known to be deficient in patients with 
T2DM,20,21 and GLP-1 infusion has been shown experimen-
tally to lower glucose levels via enhanced glucose-dependent 
insulin secretion in subjects with T2DM.22–24 Further study 
with GLP-1 in subjects with T2DM has demonstrated 
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glucagon secretion,25,26 slowing of gastric emptying,27,28 and 
increased satiety and decreased food intake.29
While GLP-1 has demonstrated clinical utility in the man-
agement of patients with T2DM, endogenous GLP-1 is rapidly 
degraded by the enzyme DPP-4, resulting in a GLP-1 half-life 
of approximately 1–2 minutes.30 The development of DPP-4 
resistant GLP-1 analogs has been one strategy by which to 
utilize the beneficial effects of GLP-1 in patients with T2DM. 
Liraglutide is the newest incretin analog currently available 
in the US, which is approved for once-daily administration.13 
In vitro studies indicate that liraglutide retains affinity for 
GLP-1 receptors despite these structural modifications.31 The 
addition of the C16 acyl chain allows for noncovalent binding 
to albumin, both hindering DPP-4 access to the molecule and 
contributing to a prolonged   half-life and duration of action.32
Pharmacokinetics
The structure of liraglutide makes it kinetically unique 
when compared with the related compound exenatide; lira-
glutide incorporates a palmitate side chain at position 26 
using a γ-glutamic acid spacer.33,34 This change allows for 
99%   albumin binding when compared with natural GLP-1, 
  allowing liraglutide to escape glomerular filtration and extend 
its duration of action. Liraglutide is detected in the urine 
and feces as metabolites, and is hepatically metabolized and 
eliminated via the liver and kidneys.
The pharmacokinetic profile of liraglutide makes it a 
desirable agent for the treatment of T2DM, given the extended 
time to maximum plasma concentration (Tmax) and half-life 
(t1/2). In an initial study performed by Elbrond et al, 72 healthy 
male subjects received 8 consecutive subcutaneous doses 
(1.25–20.0 µg/kg per dose) of liraglutide.35 Results from 
this study reported a Tmax of 9–12 hours after dosing, and a 
plasma t1/2 of elimination of 11–15 hours.35 In a study of 30 
healthy male subjects receiving 5 consecutive subcutaneous 
doses (1.25–12.5 µg/kg per dose) of liraglutide, the reported 
Tmax was 10–14 hours, while the plasma t1/2 of elimination 
was 11–13 hours.34 Further kinetic studies were performed 
utilizing liraglutide in a multi-day fashion with different 
administration times. One study was performed in 11 subjects 
with T2DM, administering 10 µg/kg subcutaneously once 
daily at bedtime for 1 day.36 The Tmax was found to be 10–14 
hours, consistent with previous studies, while the plasma t1/2 
was found to be 6–14 hours. A second study was performed 
with liraglutide, administering 6 µg/kg subcutaneously every 
morning over a 7-day period in 13 T2DM subjects.37 Study 
results reported a Tmax of 7.1–13.1 hours, and a steady-state 
plasma t1/2 of 17.9 hours.
Liraglutide was also examined in clinical trials to 
  determine if normal dosing pharmacokinetics would be 
impacted in both renally and hepatically impaired subjects. 
Jacobsen et al performed a study in 30 subjects, comprising 
24 with varying degrees of renal impairment and 6 healthy 
subjects, in which 0.75 mg of liraglutide was administered 
subcutaneously, with 72-hour follow-up blood sampling.38 
Results from this study found that liraglutide did not 
adversely impact serum creatinine in mild-to-severe renal 
impairment, and was not associated with an increased risk of 
adverse events in this study population. A meta-analysis was 
performed examining the Phase III LEAD studies, looking at 
the impact of liraglutide on serum creatinine levels.39 When 
compared with normal subjects, no significant change in 
serum creatinine occurred with either 1.2 mg daily or 1.8 mg 
daily dosing; this is considered to be due to the modification 
of liraglutide’s chemical structure when compared with natu-
ral GLP-1. Liraglutide was also evaluated in 24 subjects with 
mild, moderate, severe, or no hepatic impairment.40 Subjects 
were administered 0.75 mg of liraglutide as a single dose, and 
were evaluated after a 72-hour period to determine if hepatic 
impairment influenced liraglutide’s kinetic and safety profile. 
After both renal and hepatic evaluations, it was concluded by 
the researchers that no hepatic or renal dosing adjustments 
are necessary with liraglutide.
When compared with exenatide, there are several 
  differences that may be advantageous when considering the 
use of liraglutide. Exenatide was directly compared with 
liraglutide in the LEAD-6 trial to determine the efficacy and 
safety of each agent.41 Subjects were administered either 
1.8 mg/day of liraglutide (202 subjects) or 10 µg twice daily 
of exenatide (187 subjects) for a period of 26 weeks. It was 
found that liraglutide maintained steady-state plasma levels 
24 hours after administration, while exenatide peaked and 
returned to baseline plasma levels 10–12 hours following 
administration. Liraglutide was also found to have minimal 
impact on renal function due to its chemical structure, while 
exenatide is primarily eliminated through the kidney, and 
is not recommended for use in severe renal impairment or 
end-stage renal disease.1
Clinical trials
The LEAD program comprises 6 randomized, controlled, 
double-blind Phase III clinical studies in participants with 
T2DM inadequately controlled with lifestyle and dietary 
interventions or oral antidiabetic therapies. Table 1 provides 
a summary of select efficacy endpoints reported from the 
six LEAD studies discussed individually below.42–47 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Liraglutide versus rosiglitazone  
as add-on to baseline glimepiride
LEAD-1 was a 26-week, randomized, double-dummy trial in 
1041 patients with T2DM. The objective of the study was to 
compare the addition of liraglutide to glimepiride therapy with 
glimepiride monotherapy or the addition of rosiglitazone to 
baseline glimepiride.42 Participants had a mean baseline HbA1c 
of 8.4% and a mean age of 56.1 years. Participants received 
liraglutide 0.6 mg/day, 1.2 mg/day, or 1.8 mg/day in combina-
tion with glimepiride, placebo plus glimepiride (2–4 mg/day), 
or rosiglitazone 4 mg/day plus glimepiride. Mean HbA1c was 
reduced by −1.08% and −1.13% with liraglutide 1.2 mg and 
1.8 mg, respectively. Participants receiving rosiglitazone expe-
rienced a mean HbA1c reduction of −0.44%, and glimepiride 
monotherapy resulted in a mean HbA1c increase of 0.23% 
(P , 0.0001). Of those treated with liraglutide 1.2 mg plus 
glimepiride, 22% reached an HbA1c less than 6.5%, with 21% 
reaching an HbA1c less than 6.5% with liraglutide 1.8 mg plus 
glimepiride. In contrast, 4% of those on glimepiride mono-
therapy and 10% of subjects treated with rosiglitazone plus 
glimepiride reached an HbA1c below 6.5% (P , 0.0003).
Liraglutide versus glimepiride  
as add-on to baseline metformin
LEAD-2 was a randomized, double-blind study that enrolled 
1091 participants with T2DM.43 Participants had a mean 
baseline HbA1c of 8.4%. Participants received liraglutide 
0.6 mg, 1.2 mg, or 1.8 mg once daily added to metformin 1 
g twice daily, placebo plus metformin, or glimepiride 4 mg/
day added to metformin. Mean HbA1c reductions of −0.7%, 
−1.0%, and −1.0% were observed with liraglutide 0.6 mg, 1.2 
mg, and 1.8 mg in combination with metformin, respectively. 
Those receiving metformin monotherapy experienced a mean 
HbA1c increase of 0.1%, with a decrease of −1.0% seen in 
those receiving glimepiride plus metformin (P , 0.05 versus 
liraglutide plus metformin versus placebo plus metformin). 
Weight loss was achieved in all participants receiving lira-
glutide, compared with a 1.0 kg weight gain observed in 
those receiving glimepiride (P , 0.0001 for all liraglutide 
doses when compared with glimepiride). The percentage 
of patients achieving an HbA1c less than 6.5% was 11.3% 
in the liraglutide 0.6 mg plus metformin group, 19.8% in 
the liraglutide1.2 mg plus metformin group, and 24.6% in 
Table 1 Select efficacy outcomes from the Liraglutide Effects and Action in Diabetes (LEAD) trials
Pts Treatment Treatment  
period  
(weeks)
HbA1C  
Change  
(%)
Achievement  
of HbA1C , 7%  
(%)
FPG  
change  
(mg/dL)
PPG  
change  
(mg/dL)
BW  
change  
(kg)
Background Intervention
LeAD-142 1041 Glim 2–4 mg/day Lir 0.6 mg/day 
Lir 1.2 mg/day 
Lir 1.8 mg/day 
Ros 4 mg/day 
Placebo
26 −0.6a 
−1.08a,b 
−1.13a,b 
−0.44a 
+0.23
24a 
35a,c 
42a,d 
22 
8
−13.0a 
−28.3a,e 
−28.6a,e 
−15.8 
+18.2
−32.4a 
−45.0a,f 
−48.6a,g 
−32.4 
−7.2f
+0.7b 
+0.3b 
−0.2b 
+2.1 
−0.1
LeAD-243 1091 Met 1 g twice daily Lir 0.6 mg/day 
Lir 1.2 mg/day 
Lir 1.8 mg/day 
Glim 4 mg/day 
Placebo
26 −0.7a 
−1.0a,h 
−1.0a,h 
−1.0a 
+0.1
28.0i 
35.3i 
42.4i 
36.3 
10.8
−19.8a 
−28.8a 
−30.6a 
−23.4a 
+7.2
−30.6j 
−41.4j 
−46.8j 
−45.0j 
−10.8
−1.8b 
−2.6b,k 
−2.8b,k 
+1.0 
−1.5
LeAD-344 746 Diet/exercise 
50% maximum 
dose of OAD 
monotherapy
Lir 1.2 mg/day 
Lir 1.8 mg/day 
Glim 8 mg/day
52 −0.84l 
−1.14b 
−0.51
42.8m 
50.9b 
27.8
−15.1n 
−25.6b 
−5.2
−30.8 
−37.4o 
−24.5
−2.1b 
−2.5b 
+1.1
LeAD-445 533 Met 1 g twice daily 
Ros 8 mg/day
Lir 1.2 mg/day 
Lir 1.8 mg/day 
Placebo
26 −1.48a 
−1.48a 
−0.54
57.5a 
53.7a 
28.1
−40a 
−44a 
−8
−47j 
−49j 
−14
−1.0p 
−2.0p 
+0.6
LeAD-546 581 Met 1 g twice daily 
Glim 4 mg/day
Lir 1.8 mg/day 
insulin glargine 
Placebo
26 −1.33a,b 
−1.09 
−0.24
53.1a,q 
45.8 
15.5
−27.9a 
−32.2 
+9.5
−32.6a 
−29.0 
−0.5
−1.8a,b 
+1.6 
−0.4
LeAD-641 464 Met 
SU
Lir 1.8 mg/day 
exen 10 µg bid
26 −1.12b 
−0.79
54r 
43
−29.0b 
−10.8
NRs 
NR
−3.2 
−2.9
Notes: aP # 0.0001 versus placebo; bP , 0.0001 versus comparator; cP = 0.0005 versus comparator; dP , 0.0001 versus comparator; eP ,0.01 versus comparator; fP = 0.043 
versus comparator; gP = 0.0022 versus comparator; hnoninferior to active comparator; iP , 0.02 versus placebo; jP , 0.001 versus placebo; kP # 0.01 versus placebo; 
lP = 0.0014 versus comparator; mP = 0.0007 versus comparator; nP = 0.027 versus comparator; oP = 0.0038 versus comparator; PP , 0.05 versus placebo; qP = 0.0139 versus 
comparator; rP = 0.0015 versus comparator; sAverage reduction reported to be significantly greater for exenatide when compared with liraglutide.
Abbreviations: HbA1c, hemoglobin HbA1c; Bw, body weight; exen, exenatide; FPG, fasting plasma glucose; Glim, glimepiride; Lir, liraglutide; NR, not reported; OAD, oral 
antidiabetic drug; PPG, postprandial glucose; Pts, participants randomized; Ros, rosiglitazone; SU, sulfonylurea. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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the liraglutide 1.8 mg plus metformin group, compared with 
4.2% of those treated with placebo plus metformin, and 22.2% 
of those treated with glimepiride plus metformin (P , 0.02 
for all liraglutide doses when compared with placebo).
Liraglutide versus glimepiride  
as monotherapy
The LEAD-3 study enrolled 746 patients with T2DM and a 
mean baseline HbA1c of 8.2%.44 This Phase III, double-blind, 
parallel-treatment study involved a head-to-head comparison 
of monotherapy with 1.2 mg/day or 1.8 mg/day of liraglutide or 
glimepiride 8 mg/day. Any previous oral antidiabetic drugs (up 
to half the maximal dose) were discontinued at randomization 
prior to study drug initiation. At 52 weeks of therapy, mean 
HbA1c reductions from baseline of −0.84% (P = 0.0014 versus 
glimepiride) and −1.4% (P , 0.0001 versus glimepiride) were 
seen with liraglutide 1.2 mg and 1.8 mg, compared with a 
reduction of −0.51% for glimepiride. Twenty-seven percent of 
patients on liraglutide 1.8 mg and 16% of patients on glimepir-
ide attained an HbA1c less than 6.5%. Decreases in body weight 
observed were −2.1 kg and −2.5 kg for liraglutide 1.2 mg and 
1.8 mg, respectively (P = 0.0001 versus glimepiride for both 
doses). In contrast, participants receiving glimepiride experi-
enced an average weight gain of 1.1 kg.
Liraglutide as add-on to baseline 
metformin and rosiglitazone
LEAD-4 was a 26-week, placebo-controlled trial enrolling 533 
patients with T2DM and a mean baseline HbA1c of 8.3%.45 
LEAD-4 assessed the effect of adding liraglutide 1.2 mg or 
1.8 mg to baseline metformin 1 g twice daily plus rosiglita-
zone 8 mg/day. Liraglutide addition resulted in mean HbA1c 
reductions of −1.48% for both liraglutide doses compared with 
−0.54% observed with the addition of placebo (P = 0.0001). 
An HbA1c less than 6.5% was achieved in 35% and 37% of 
patients receiving liraglutide 1.2 mg and 1.8 mg, respectively. 
Liraglutide 1.2 mg and 1.8 mg treatment resulted in reduc-
tions in fasting plasma glucose (−40 mg/dL and −43 mg/dL, 
respectively) and postprandial glucose levels (−49 mg/dL and 
−47 mg/dL, respectively). Patients receiving placebo experi-
enced a mean increase in body weight of 0.6 kg compared with 
a mean weight loss of −1.0 kg and −2.0 kg for liraglutide 1.2 and 
1.8 mg (P , 0.05 versus placebo for both liraglutide doses).
Liraglutide versus glargine as add-on  
to baseline metformin and glimepiride
LEAD-5 aimed to compare liraglutide with insulin glargine 
as add-on therapy to metformin and glimepiride.46 LEAD-5 
enrolled a total of 581 patients with T2DM with a mean   baseline 
HbA1c of 8.2%. Participants received liraglutide 1.8 mg/day, 
liraglutide placebo, or insulin glargine in addition to metformin 
1 g twice daily and glimepiride (2–4 mg/day) for a duration of 
26 weeks. The dose of insulin glargine was individually titrated 
according to a patient-driven algorithm, with a mean dose of 
24 units per day reported at the end of the trial in the insulin 
glargine arm. Mean HbA1c values were decreased −1.33%, 
−0.24%, and −1.09% with the addition of liraglutide, placebo, 
and insulin glargine, respectively (P , 0.05 for liraglutide ver-
sus placebo and insulin glargine). An HbA1c below 6.5% was 
achieved in 37.1% of patients treated with liraglutide, 10.9% 
of those treated with placebo (P , 0.0001 versus liraglutide), 
and 23.6% of patients in the insulin glargine group (P = 0.0001 
versus liraglutide). A mean body weight reduction of −1.81 kg 
was reported in the liraglutide group (P , 0.0001 versus 
glargine; P = 0.0001 versus placebo), with a mean weight loss 
of −0.42 kg in the placebo group, and a 1.62 kg weight gain 
seen in the insulin glargine group.
Liraglutide versus exenatide  
as add-on to baseline metformin  
and/or a sulfonylurea
LEAD-6 was a 26-week trial in 464 patients inadequately 
treated with metformin and/or a sulfonylurea with a mean 
baseline HbA1c of 8.2%.41 This trial aimed to compare lira-
glutide 1.8 mg/day to exenatide 10 µg twice daily as add-on 
therapy. HbA1c reductions of −1.12% for liraglutide and 
−0.79% for exenatide were observed (P , 0.0001). A target 
HbA1c less than 6.5% was achieved in 35% of those treated 
with liraglutide versus 21% for patients receiving exenatide 
(P , 0.0001). Changes in body weight were similar in both 
groups with no statistical differences in weight change 
between the liraglutide and exenatide treatment groups. 
Weight reductions of −3.2 kg and −2.9 kg for liraglutide and 
exenatide were observed, respectively.
Additional clinical endpoints
Clinical studies with liraglutide have also demonstrated poten-
tial benefits of therapy on β-cell function and the cardiovas-
cular system. One study utilized a graded glucose protocol to 
assess the effects of a single liraglutide dose of 7.5 µg/kg on 
insulin secretion.47 Insulin secretion increased with   elevation 
in blood glucose in all groups, however liraglutide treatment 
resulted in a more pronounced insulin response which was 
similar to that observed in healthy control subjects. Other 
clinical studies have shown   improvements in glucose-  induced 
insulin secretion, β-cell sensitivity, and suppression of  Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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24-hour glucagon secretion following 1 week of therapy,37 
and sustained β-cell sensitivity to glucose over 12 weeks of 
therapy.48 Regarding the effects of liraglutide treatment on 
cardiovascular health, statistically significant decreases in 
systolic blood pressure, ranging from 2 to 7.9 mmHg, have 
been observed in clinical trials.43,44,49 The mechanism result-
ing in the observed reduction in systolic blood pressure is 
unknown, but appears unrelated to   concomitant weight loss.50 
Early data additionally indicates liraglutide treatment may 
also decrease cardiovascular markers such as PAI-1 and BNP, 
but the clinical implications, either positive or detrimental, of 
these findings are unknown.
Safety and tolerability
Hypoglycemia
Of paramount importance in any newly approved drug used 
to treat T2DM is the likelihood of hypoglycemia, when used 
as mono-, dual-, or even as part of a triple-therapy regimen. 
In the LEAD trials, a minor hypoglycemic event was defined 
as a plasma glucose concentration of ,56 mg/dL that was 
resolved with self-treatment, and a major hypoglycemic event 
was defined as a hypoglycemic event requiring third party 
assistance. Note that in LEAD-1, self-treatment was the sole 
criteria used to classify a hypoglycemic event as minor.42 As 
expected, trials utilizing combination sulfonylurea therapy 
resulted in the highest incidence of hypoglycemia. LEAD-1 
involved patients on concurrent sulfonylurea therapy 
(glimepiride).42 In this trial, the percentage of patients expe-
riencing minor hypoglycemia was reported as glimepiride 
monotherapy (placebo) 2.6%, 0.17 events/subject-year; 
liraglutide 0.6 mg, 5.2%, 0.17 events/subject-year; liraglutide 
1.2 mg 9.2%, 0.51 events/subject-year; liraglutide 1.8mg, 
8.1%, 0.47 events/subject-year; and rosiglitazone 4.3%, 
0.12 events/subject-year. Table 2 provides a summary of 
adverse event findings from the LEAD program. Further-
more, in the 1.8 mg liraglutide plus glimepiride cohort, one 
major hypoglycemic event occurred.42
In LEAD-2, the percentage of patients experiencing minor 
hypoglycemia was low in the placebo and liraglutide cohorts, 
roughly 3%, while 17% of subjects receiving glimepiride 
reported an incidence of minor hypoglycemia.43 Major 
hypoglycemic events did not occur in LEAD-2. There were 
Table 2 Adverse drug event rates in Liraglutide Effects and Action in Diabetes (LEAD) trials
Study Drug Patients  
experiencing  
minor  
hypoglycemia  
(%)
Major  
hypoglycemic  
events (n)
Nausea  
(%)
Vomiting  
(%)
GI  
events  
(%)
Pancreatitis 
(number of  
subjects)
Pulse  
rate  
(bpm)
Liraglutide   
antibody  
formation  
(%)
LeAD-142 Liraglutide 0.6 mg 5.2 0 NR NR NR 1 +2–4ab 9–13a
Liraglutide 1.2 mg 9.2c,d 0 10.5 4.4 NR 0
Liraglutide 1.8 mg 8.1e 1 NR NR NR 0
Rosiglitazone 4 mg 4.3 0 NR NR NR 0 +1 NA
Placebo 2.6 0 1.8 NR NR 0 −1 NA
LeAD-243 Liraglutide 0.6 mg 3af 0 11 5–7a 35 0 +2–3ag NR
Liraglutide 1.2 mg 16 40 1 NR
Liraglutide 1.8 mg 19 44 0 NR
Glimepiride 4 mg 17 0 NR 1 17 1 +1 NA
Placebo 3 0 NR 1 17 0 +1 NA
LeAD-344 Liraglutide 1.2 mg 12f 0 27.5f 9.3 49 1 +3.2h NR
Liraglutide 1.8 mg 8f 0 29.3f 12.4 51 1 +1.6 NR
Glimepiride 8 mg  24 0 8.5 3.6 26 0 +0.4 NA
LeAD-445 Liraglutide 1.2 mg 9.0 0 29 7 45 0 +2 4.1
Liraglutide 1.8 mg 7.9i 0 40 17 56 0 +3 6.7
Placebo 5.1 0 NR NR 19 0 −0.5 0
LeAD-546 Liraglutide 1.8 mg 27.5 5 13.9 6.5 NR 0 +2.62 9.8
insulin glargine 28.9 0 1.3 0.4 NR 0 +0.08 NA
Placebo 16.7 0 3.5 3.5 NR 0 +0.93 NA
LeAD-641 Liraglutide 1.8 mg 26j 0 25.5 6.0 45.5 1 +3.28k NR
exenatide 10 µg bid 34 2 28.0 9.9 42.7 0 +0.69 NA
Notes: aReported composite for all liraglutide doses tested; bP # 0.002 versus placebo; cP = 0.0024 versus comparator; dP = 0.048 versus placebo; eP = 0.0065 versus 
comparator; fP , 0.001 versus comparator; gP , 0.03 for 0.6 mg and 1.2 mg liraglutide groups versus comparator; hP = 0.0027 versus comparator; iP = 0.004 versus placebo; 
jP = 0.0131 versus comparator; kP = 0.0012 versus comparator.
Abbreviations: bid, twice daily; bpm, beats per minute; Gi, gastrointestinal; NA, not applicable; NR, not reported. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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a low percentage of patients reporting minor hypoglycemic 
events in LEAD-3, with 8% of the subjects in the liraglutide 
1.8 mg group (0.25 events per year) and 12% of subjects in 
the 1.2 mg group experiencing minor hypoglycemic events 
(0.3 events per year).44 Twenty-four percent of subjects in 
the glimepiride group reported minor hypoglycemic events 
while no major hypoglycemic events occurred in any of the 
groups in this 52-week trial.
Minor hypoglycemia was reported in LEAD-4 at rates 
of 9%, 7.9%, and 5.1% of subjects in the 1.2 mg liraglutide, 
1.8 mg liraglutide, and placebo groups, respectively.45 No major 
hypoglycemic events were reported. In LEAD-5, 27.4% of the 
patients receiving liraglutide experienced at least 1 episode of 
minor hypoglycemia (1.2 events/subject/year), while 28.9% 
(1.3 events/subject/year) and 16.7% (1.0 events/subject/year) 
experienced minor hypoglycemia in the insulin glargine and 
placebo groups, respectively.46 In the liraglutide group, 5 sub-
jects reported a major hypoglycemic episode, with no major 
hypoglycemic events reported in the other two cohorts.
In the open-label 26-week trial known as LEAD-6, minor 
hypoglycemia occurred in 26% and 34% of the liraglutide 
and exenatide groups, respectively; correlating to event rates 
of 1.9 (liraglutide) and 2.6 (exenatide) events per subject per 
year.41 Two cases of major hypoglycemia occurred in subjects 
exposed to exenatide and a sulfonylurea.
Gastrointestinal adverse events
In the LEAD-1 trial, incomplete data were provided for 
all arms of the study in regard to gastrointestinal (GI) side 
effects.42 The most complete data reveal that nausea was 
highest in the liraglutide 1.2 mg cohort (10.5%) compared 
with an event rate of 1.8% in the placebo group. Addition-
ally, 4.4% and 7.9% of those in the 1.2 mg liraglutide group 
experienced vomiting and diarrhea, respectively.
The LEAD-2 trial involved subjects on a wide range of 
oral therapies that included metformin, sulfonylureas, repa-
glinide, or some combination of these listed medications.43 
GI adverse events were pronounced in this trial, with 35% of 
the subjects in the 0.6 mg liraglutide group experiencing GI 
side effects, including nausea, vomiting, and diarrhea, with 
40% and 44% experiencing these GI-related adverse events 
in the 1.2 mg and 1.8 mg groups, respectively. This is in 
comparison with 17% of the placebo-treated group reporting 
GI-associated adverse events. Five percent (36 subjects) of 
those receiving any dose of liraglutide withdrew from the 
study due to GI-related adverse events.
In LEAD-3, nausea occurred in 27.5%, 29.3%, and 8.5% 
of participants in the 1.2 mg liraglutide, 1.8 mg liraglutide, 
and glimepiride groups, respectively.44 Vomiting occurred in 
3.6% of subjects receiving glimepiride, while this side effect 
occurred in 9.3% and 12.4% of those receiving 1.2 mg and 
1.8 mg of liraglutide, respectively. Diarrhea was reported 
by 15.5%, 18.7%, and 8.9% of participants in the 1.2 mg 
liraglutide, 1.8 mg liraglutide, and glimepiride groups, 
respectively. A total of 6 participants (1.2%) receiving lira-
glutide withdrew from the study due to vomiting, while a 
total of 17 participants (3.4%) receiving liraglutide withdrew 
for any GI-related complaint. In the 26-week study known 
as LEAD-4, 29% of subjects receiving 1.2 mg liraglutide 
experienced nausea while 40% of subjects in the 1.8 mg 
liraglutide group reported this adverse event.45 Vomiting 
was reported by 7% and 17% of subjects in the 1.2 mg and 
1.8 mg liraglutide groups, respectively. When all GI adverse 
events were grouped (nausea, vomiting, diarrhea), 19% of 
those receiving placebo and 45% and 56% of those receiv-
ing 1.2 mg and 1.8 mg of liraglutide, respectively, reported 
GI-related complaints. GI adverse events contributed to 5 
withdrawals (3% of participants) in the liraglutide 1.2 mg 
group and 19 (10.7% of participants) in the liraglutide 
1.8 mg group.
Nausea occurred in 13.9% of those receiving liraglutide, 
3.5% in placebo arm, and 1.3% of participants in the insu-
lin glargine group in LEAD-5.46 In this trial, diarrhea was 
reported in 10%, 5.3%, and 1.3% in the liraglutide, placebo, 
and insulin glargine groups, respectively. Vomiting occurred in 
6.5%, 3.5%, and 0.4% in the liraglutide, placebo, and insulin 
glargine groups, respectively. Dyspepsia was also reported 
in this trial, with 6.5%, 0.9%, and 1.7% of subjects in the 
liraglutide, placebo, and insulin glargine groups, respectively, 
experiencing this GI-related adverse event. Four subjects 
in LEAD-5 receiving liraglutide withdrew from the study 
due to GI-related adverse events. LEAD-6 reported similar 
rates of GI-related adverse events between the liraglutide 
and exenatide groups.41 Overall, GI adverse events occurred 
in 45.5% and 42.7% of liraglutide- and exenatide-treated 
subjects, respectively, with nausea being the most frequently 
reported event. Nausea tended to resolve over time with both 
therapies, however, with 2.5% of the liraglutide group report-
ing nausea at week 26 compared with 15.8% of those receiving 
exenatide therapy.41 Vomiting occurred in 6.0% and 9.9% of 
the liraglutide and exenatide groups, respectively.
From the above data it can be seen that nausea is a 
  frequent adverse event in subjects receiving liraglutide. 
However, nausea was most pronounced in the first 4 weeks 
of therapy, with symptoms generally dissipating over the 
remainder of the study period in all trials. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Pulse rate
The effects of liraglutide on pulse rate ranged from an 
increase of 2–4 beats per minute (bpm) in subjects receiv-
ing liraglutide (P # 0.002 versus placebo; P , 0.01 versus 
rosiglitazone), with pulse increasing by a mean 1 bpm in 
subjects receiving rosiglitazone, and pulse decreasing by 
a mean 1 bpm in the placebo group.42 In the LEAD-2 trial, 
pulse rates increased by a mean 2–3 bpm in those receiving 
liraglutide, compared with a 1 bpm increase in the glimepiride 
and placebo groups.43 The mean pulse rate in LEAD-3 
increased by 0.4, 3.2, and 1.6 bpm for the glimepiride group 
and the 1.2 mg and 1.8 mg liraglutide groups, respectively.44 
Pulse rate increased by 2 bpm in subjects receiving liraglutide 
in LEAD-4, with mean pulse rates increasing by 3 bpm in 
those receiving liraglutide 1.8 mg.45 Pulse rate increased by 
a mean of 2.62 bpm in those subjects receiving liraglutide 
in LEAD-5, while increases of 0.08 bpm and 0.93 bpm were 
experienced by those in the insulin glargine and placebo 
groups, respectively.46 In LEAD-6, heart rates increased by 
a mean of 3.28 bpm in the liraglutide group compared with 
0.69 bpm in the exenatide group.41
Pancreatitis
Pancreatitis has been reported in clinical trials with lira-
glutide. In LEAD-1, one subject receiving liraglutide 
0.6 mg developed pancreatitis but successfully completed 
the trial.42 Two subjects withdrew from the LEAD-2 study 
after   developing pancreatitis, 1 receiving liraglutide and 1 
receiving glimepiride.43 1 participant in each of the liraglutide 
groups in LEAD-3 developed pancreatitis, with one complet-
ing the trial.44 No cases of pancreatitis were reported in the 
26-week LEAD-4 or LEAD-5 trials.45,46 Likewise, no cases of 
acute pancreatitis were reported in LEAD-6; however 1 case 
of mild pancreatitis occurred in a subject receiving liraglutide 
who subsequently completed the 26-week trial.41
Anti-liraglutide antibodies
In LEAD-1, 9%–13% of subjects exposed to liraglutide 
during the 26-week trial developed anti-liraglutide antibod-
ies.42 The LEAD-2 and LEAD-3 trials did not measure the 
development of liraglutide antibody formation. In LEAD-4, 
6 subjects in the liraglutide 1.2 mg group and 9 subjects 
in the liraglutide 1.8 mg group developed antibodies.45 In 
LEAD-5, 23 subjects (9.8%) of subjects developed anti-
liraglutide antibodies   during the 26-week study.46 Because 
the LEAD-6 trial involves an extension phase where subjects 
may continue to take liraglutide, antibody determination 
will be completed once the trial is complete and after an 
  appropriate washout period; these data are not currently 
available.41 While the clinical impact of anti-liraglutide 
antibodies is unknown at this time, further study of this 
phenomenon is warranted.
Additional safety considerations
Study withdrawal rates due to adverse drug events and 
event rates for serious adverse events reported in the six 
LEAD trials are summarized in Table 3. Interestingly, 
injection-related adverse events such as injection site rash, 
were not reported in any of the LEAD trials. In addition 
to the adverse drug events discussed above, peripheral 
edema was reported in the LEAD-4 trial, likely due to 
participants also receiving concomitant rosiglitazone.45 
In this trial, peripheral edema occurred in 5.1%, 1.7%, 
and 8.0% of the subjects in the 1.2 mg liraglutide, 1.8 mg 
liraglutide, and placebo groups, respectively. The LEAD 
studies indicate liraglutide to be generally safe, however 
the development of rare adverse events is of concern until 
patients at heightened risk for developing events such as 
pancreatitis can be identified. The safety and tolerability 
of liraglutide can only truly be assessed with robust Phase 
IV post-marketing data involving long-term treatment with 
this novel therapy.
An additional theoretical concern raised in the   liraglutide 
prescribing information is a warning regarding the observa-
tion of dose-dependent and treatment-duration-dependent 
thyroid C-cell tumors witnessed at clinically relevant 
exposures in rats and mice.13 During clinical trials with 
liraglutide, calcitonin, a biomarker for the detection of med-
ullary thyroid cancer, was monitored routinely.51 During the 
LEAD program, increases in calcitonin levels did occur in a 
slightly higher percentage of patients treated with liraglutide 
when compared with controls, however, calcitonin levels 
remained within normal ranges.51 Ultimately, while it is 
unknown if this is clinically relevant in humans, liraglutide 
is contraindicated in patients with a personal or family his-
tory of medullary thyroid carcinoma, and in patients with 
multiple endocrine neoplasia syndrome type 1.13 The FDA 
has requested the establishment of a cancer registry to moni-
tor the annual incidence of medullary thyroid cancer over 
the next 15 years.51
Administration
Liraglutide was approved in July of 2009 by the European 
Commission for marketing consideration to all 27 Euro-
pean Union members.52 Liraglutide is administered as a  Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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  subcutaneous injection for once-daily treatment of T2DM, as 
an adjunct therapy in combination with metformin, a sulfony-
lurea, or metformin plus a sulfonylurea or   thiazolidinedione.53 
The approved dosing for use in Europe is an initial dose of 
0.6 mg daily for one week, with a recommended titration 
to 1.2 mg daily after the first week. The maximum recom-
mended daily dose is 1.8 mg for patients who are not well 
controlled and who can tolerate the higher titrated dose, 
although doses as high as 2 mg daily have been used in clini-
cal trials.54 The LEAD studies found that titrating liraglutide 
by 0.6 mg weekly improved the tolerability and reduced the 
occurrence of GI adverse events.43 Injection site reactions 
are another concern, and should be monitored for during 
liraglutide initiation.13 Liraglutide received FDA approval 
for use in the US in January 2010 as an adjunct to diet and 
exercise to improve glycemic control in adults with T2DM.13 
Similar to Europe, in the US liraglutide is recommended at a 
starting dose of 0.6 mg daily for the first week, followed by 
an upward titration to 1.2 mg daily.13 For those patients not 
achieving the desired glycemic control at the 1.2 mg dose, 
the dose can likewise be increased to 1.8 mg. As per the pre-
scribing information, it is also recommended that a reduction 
in the dose of pre-existing insulin secretagogue medications 
be considered when initiating liraglutide to minimize the 
risk of treatment-emergent hypoglycemia.13 Liraglutide is 
available commercially in the US as a simple pen capable of 
administering 0.6, 1.2, and 1.8 mg doses.
Patient-specific considerations
A common problem among T2DM patients is the issue of 
weight management. Elevated body weight or obesity, and 
an increased risk of cardiovascular-related complications 
often increase the medical burden and medication load of 
the patient.55 The patient is often prescribed a medication 
regimen that is counterproductive to weight loss, which 
decreases treatment satisfaction due to resulting weight 
gain. Newer GLP-1 agonists, such as exenatide and lira-
glutide, are associated with weight reduction in healthy and 
diabetic subjects.41 A comparative trial of exenatide and 
liraglutide in T2DM subjects concluded that both exenatide 
and liraglutide were associated with a significant reduction 
in body weight when compared with baseline (−2.87 kg and 
−3.24 kg, respectively).41 In the LEAD-3 trial, weight loss 
was reported in both the 1.2 mg and 1.8 mg liraglutide mono-
therapy groups, with an average loss of −2 kg and −2.5 kg, 
respectively (P , 0.0001).44 Reported weight loss occurred 
during the first 16 weeks, but was sustained throughout the 
remaining 36 weeks of treatment. After completion of a sec-
ond 52-week open-label study period, weight reductions of 
−2.1 kg and -2.7 kg for both the 1.2 mg and 1.8 mg liraglutide 
Table 3 Clinical study withdrawal and serious adverse event rates in Liraglutide Effects and Action in Diabetes (LEAD) trials
Study Drug Discontinuation due to ADEa (%) Serious adverse eventsb
LeAD-142 Liraglutide 0.6 mg 20 3%
Liraglutide 1.2 mg 34 4%
Liraglutide 1.8 mg 43 5%
Rosiglitazone 4 mg 19 3%
Placebo 19 3%
LeAD-243 Liraglutide 0.6 mg 32 NR
Liraglutide 1.2 mg 52 NR
Liraglutide 1.8 mg 57 NR
Glimepiride 4 mg 23.5 NR
Placebo 4 NR
LeAD-344 Liraglutide 1.2 mg 28 16 subjects/18 events
Liraglutide 1.8 mg 24 8 subjects/9 events
Glimepiride 8 mg 16 13 subjects/17 events
LeAD-445 Liraglutide 1.2 mg 44 8 subjects/8 events
Liraglutide 1.8 mg 60 7 subjects/10 events
Placebo 10.7 12 subjects/13 events
LeAD-546 Liraglutide 1.8 mg 48 NR
insulin glargine 38.5 NR
Placebo 5.5 NR
LeAD-641 Liraglutide 1.8 mg 70 5.1%
exenatide 10 µg bid 69 2.6%
Notes: aPercentage of the total number of subject dropouts who withdrew due to an adverse drug event; bReported either as a percentage of study subjects or number of 
subjects and number of events.
Abbreviations: ADe, adverse drug event; NR, not reported. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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study groups, respectively, were significant when compared 
with those receiving glimepiride (P , 0.0001).44 In all LEAD 
studies completed, liraglutide 1.8 mg daily was associated 
with reported weight reductions of −0.2 kg to −3.24 kg over 
a period of at least 6 months.41–46 Of additional interest, an 
analysis of patients from LEAD-1 and LEAD-2 reported 
that weight reductions in patients receiving liraglutide were 
primarily due to reductions in fat mass rather than lean tissue 
mass.56 Finally, a trial enrolling healthy, nondiabetic patients 
with a mean baseline BMI of 30–40kg/m2 compared the 
weight effects of liraglutide at doses of 1.2, 1.8, 2.4, and 3 mg 
daily, versus orlistat 120 mg three times daily or placebo.57 
Weight loss in liraglutide subjects was −4.8 kg in the 1.2 mg 
group (P = 0.003), −5.5 kg in the 1.8 mg group (P , 0.0001), 
−6.3 kg in the 2.4 mg group (P , 0.0001), and −7.2 kg in the 
3.0 mg group (P , 0.0001) when compared with baseline.
Quality of life was another indicator of treatment outcome 
that was evaluated in select clinical trials. Astrup et al found 
that mean physical function improved in the liraglutide 3.0 mg 
group by a score of 6.8 (P = 0.001) when compared with pla-
cebo, and by 6.0 when compared with the orlistat treatment 
group (P = 0.006).57 Mean self-esteem also increased in the 
3.0 mg daily group by a score of 9.6 when compared with 
placebo (P = 0.0001), and by 6.2 when compared with the 
orlistat treatment group (P = 0.04). Patient-reported outcomes 
were also investigated in the LEAD-3 trial. Compared with 
glimepiride, the liraglutide 1.8 mg cohort reported a mean 
decrease in BMI that was associated with improvements 
in both weight image and weight concern (P , 0.0001).44 
Decreases in weight concern were associated with increases 
in overall quality of life, general perception of their health 
(both P , 0.0001), and mental/emotional health (P = 0.002). 
Finally, in LEAD-6, subjects were assessed for treatment 
satisfaction using the Diabetes Treatment Satisfaction Ques-
tionnaire.41 Overall treatment satisfaction was reported to be 
significantly higher in the liraglutide group when compared 
with the exenatide group (P = 0.0004).
Future studies regarding adherence and continued impact 
on patient quality of life would be of value to the clinical 
community, with the unique kinetic parameters of liraglutide, 
as well as its positive impact on weight, lending merit to 
liraglutide as a viable option for the treatment of T2DM.
Discussion
The pharmacokinetic profile of liraglutide is amenable 
to once-daily dosing, thus creating a potential advantage 
when compared with twice-daily exenatide. Drug regimen 
  simplicity is an important clinical consideration, particularly 
in patients receiving multiple medications for the treatment 
of T2DM and related comorbidities. Patients often present 
with resistance to the initiation of an   injectable agent, how-
ever the potential for weight loss with the incretin mimetics 
and incretin analogs can be a motivator for some patients. 
The most recent consensus algorithm released by the ADA 
and the European Association for the Study of Diabetes lists 
GLP-1 analogs as a treatment option for consideration as 
a Tier 2 agent, or “less well-validated therapy”, in T2DM 
patients.9 The consensus guideline recommends consider-
ation of GLP-1 agonist therapy in selected clinical situa-
tions. One situation in which GLP-1 agonist therapy could 
be considered is if weight loss is a major consideration and 
the patient’s HbA1c level is close to target (,8.0%).9 The 
guideline warns, however, that GLP-1 agonist therapy is not 
indicated for all patients and should be used with caution 
in those with a history of significant GI disease, such as a 
diagnosis of gastroparesis, due to a possible exacerbation 
of such conditions with incretin mimetic therapy.9 Because 
postprandial hyperglycemia affects HbA1c to a greater 
degree than fasting hyperglycemia, the closer a patient is 
to their HbA1c goal, GLP-1 agonists, such as liraglutide, 
provide a viable treatment option to target postprandial 
glucose excursions due to their glucose-dependent effects 
on insulin secretion.
Conclusion
Clinical trial data from large, controlled studies demonstrate 
the efficacy and safety of liraglutide in terms of HbA1c reduc-
tion, beneficial effects on body weight, and a low risk for 
hypoglycemic events when used as monotherapy. Liraglutide 
is relatively well tolerated, with dose-dependent nausea, vom-
iting, and diarrhea being the most commonly reported adverse 
events observed in clinical trials. Clinical trial data in humans 
indicate that liraglutide may have a role in the treatment of 
T2DM patients as monotherapy early in the disease process, 
as well as in combination with metformin, glimepiride, and 
rosiglitazone in patients inadequately controlled on oral 
antidiabetic drugs. Comparative data with exenatide twice-
daily indicate a potential therapeutic advantage for liraglutide 
in terms of ease of use, with similar improvements in HbA1c 
and body weight seen when comparing these two agents. 
Data are currently not available comparing liraglutide with 
once-weekly exenatide currently under Phase III study, 
however. Questions do remain regarding the safety of this 
agent in terms of risk of pancreatitis and medullary thyroid 
carcinoma. While the risk of such events is assumed to be 
small, vigorous postmarketing surveillance and reporting is  Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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warranted to identify patients that may be at increased risk 
for experiencing such events.
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